⌘K
H.R. Hygiene Products is a manufacturer of hygiene products with brands like Femiss, Womanica, ElderFit, and Bloom Baby, catering to various segments from babies to the elderly. The company has shown strong revenue and profit growth, operating in a growing hygiene market. The IPO is a Book Build Issue on BSE, with a mix of fresh issue and OFS.
Deterministic verdict 'Neutral': listing=62/Neutral, short=74/Neutral Positive, long=73/Apply; overall=71.5; confidence=100.0/100 | computed financials: fin=78, growth=94, D/E=0.51 (70% math / 30% model) | market signals: alignment=90 (OFS 20.0%), anchor quality=45 (marquee 13.5%), GMP trend=stable, overhang=54 | demand profile: reservation weights QIB/NII/Ret 30%/21%/49%, QIB effective demand=0.83x, institutional contribution=13%, breadth=0.90 | unlocks: anchor unlock ~13.8% of issue at T+30d, ~13.8% at T+90d | rule: mixed signals -> Neutral. | Analyst notes: H.R. Hygiene Products SME IPO is rated 'Strong Apply' due to its exceptional financial performance, including high revenue and PAT CAGRs, strong return ratios (ROE, ROCE), and an attractive post-IPO P/E valuation. The company operates in a growing hygiene market with a diversified brand portfolio and has received healthy subscription across all investor categories, including significant anchor investor participation. While there are notable risks related to operational dependencies (suppliers, contract manufacturer, logistics), product concentration, and ongoing litigations, the strong growth trajectory and favorable valuation outweigh these concerns for both short-term and long-term investors. The low GMP is a minor detractor for immediate listing gains but does not diminish the underlying fundamental strength.
| Category | Shares Offered | % of Issue | Share |
|---|---|---|---|
| QIB Shares Offered | 29,08,800 | 47.44% | |
| NII (HNI) Shares Offered | 8,73,600 | 14.25% | |
| Retail Shares Offered | 20,38,400 | 33.25% | |
| Market Maker Shares Offered | 3,10,400 | 5.06% |
| Investor | |||
|---|---|---|---|
| NECTA BLOOM VCC-NECTA BLOOM ONE | 3,20,000 | ₹2.82 Cr | 18.98% |
| MONEYWISE FINANCIAL SERVICES PVT.LTD. | 2,27,200 | ₹2 Cr | 13.47% |
| KRUSHNAM NEXUS CAPITAL TRUST-KRUSHNAM NEXUS CAPITAL SCHEME 1 | 2,27,200 | ₹2 Cr | 13.47% |
| KUBER INDIA OPPORTUNITIES FUND | 2,27,200 | ₹2 Cr | 13.47% |
| CRAFT EMERGING MARKET FUND PCC-CITADEL CAPITAL FUND | 2,27,200 | ₹2 Cr | 13.47% |
| SAINT CAPITAL FUND | 3,40,800 | ₹3 Cr | 20.21% |
| RAJASTHAN GLOBAL SECURITIES PVT.LTD. | 1,16,800 | ₹1.03 Cr | 6.93% |
Premium gain of 2.27% over issue price.
Strong historical revenue and profit growth (CAGR of 24.89% and 49.97% respectively).
Excellent return ratios (ROE 30.9%, ROCE 24.86%).
Attractive post-IPO P/E valuation of 17.53x.
Diversified brand portfolio catering to various hygiene segments.
Modern manufacturing facility and dual-channel distribution strategy.
Healthy subscription levels across all investor categories (QIB, NII, Retail).
Presence of multiple anchor investors.
Operating in a growing Indian hygiene products market (7.43% industry CAGR).
Successful execution of expansion plans, further product diversification, increased brand penetration, and effective mitigation of supply chain risks.
Continued growth in the Indian hygiene market, stable raw material prices, and sustained brand loyalty.
Intensified competition, significant disruptions in raw material supply or pricing, failure to manage operational dependencies, or adverse outcomes from ongoing litigations.
While subscription levels are strong, the low GMP (2.27%) suggests limited immediate listing pop. Investors seeking significant listing gains might find it moderate.
The company's strong financial performance, attractive valuation, and healthy subscription indicate potential for short-term appreciation post-listing, despite the low GMP.
Operating in a growing market with a diversified product portfolio and strong historical growth, the company holds good long-term potential, provided it effectively addresses operational and dependency risks.
Final verdict: Neutral (confidence High).
Positive: Exceptional revenue CAGR of 24.89% and PAT CAGR of 49.97% (FY24-FY26).
Concern: Low GMP of 2.27% suggests limited immediate listing gains.
Listing-gain vs long-term: Neutral / Apply.
Concern: High dependency on a few suppliers for raw materials and a single contract manufacturer for diapers.